1. A skin caredermatological composition comprising hyaluronic acid and at least one growth factor derived from a transgenic plant and at least one pharmaceutically andor cosmetically acceptable excipient.
2. The skin caredermatological composition of claim 1 comprising an excipient formula that stabilizes the growth factor protein.
3. The skin caredermatological composition of claim 1 wherein the hyaluronic acid is provided in a concentration in the range of about 0,01 to about 2% by weight.
4. The skin caredermatological composition of claim 1 wherein the growth factor is provided as a component of a transgenic plant extract comprised in the cosmetic composition.
5. The skin caredermatological composition of claim 4 where the growth factor is present in the transgenic plant extract in amount in the range of about 0.0001% to about 70% of the total protein content.
6. The skin caredermatological composition of claim 4 wherein said plant extract has been purified to enrich for said growth factor.
7. The skin caredermatological composition of claim 4 suitable for treatment of a skin condition selected from one or more of dry skin, eczema, dermatitis, cracked skin, rash, skin redness, scar tissue, psoriasis, and edema.
8. The skin caredermatological composition of claim 2 wherein said protein stabilizing formula comprises glycerol, water, and calcium chloride.
9. The skin caredermatological composition of claim 8 wherein said protein stabilizing formula comprises the following ingredients (% by weight): glycerol in the range from 10 to 90%, calcium chloride in the range from 0,1 mM to 200 mM, buffered in the pH range of 6-9 and purified water q.s.
10. The skin caredermatological composition of claim 8, which does not contain a further antimicrobial agent or preservative.
11. The skin caredermatological composition of claim 1 comprising more than one growth factor derived from transgenic plants.
12. The skin caredermatological composition of claim 11 where said more than one growth factor are present as components of a mixture of extracts from transgenic plants.
13. The skin caredermatological composition of claim 11 where said more than one growth factor are present in the mixture of transgenic plant extracts in an amount in the range of about 0.0001% to about 70% of the protein content.
14. The skin caredermatological composition of claim 1 wherein the at least one growth factor or more than one growth factors is isolated and purified from transgenic plants to a level of purity in the range of about 70% to about 99.9%.
15. The skin caredermatological composition of claim 1 wherein one or more plant-derived purified growth factors are added to a transgenic plant extract already containing a plant-derived growth factor.
16. The skin caredermatological composition of claim 1 wherein the at least one growth factor or more than one growth factor is selected from the group consisting of Epidermal Growth Factor (EGF), Vascular Epithelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) including PDGF-AA, PDGF-BB, and PDGF-Rb, Fibroblast Growth Factors (FGFs) including FGF-a, and FGF-b FGF-4 and FGF-6, Transforming Growth Factors-beta (TGFs-b) including TGF beta-1, TGF beta-2, TGF beta-3, Transforming Growth Factor-alpha (TGF-a), Erythropoietin (Epo), Insulin-Like Growth Factor-I (IGF-I), Insulin-Like Growth Factor-II (IGF-II), Interleukin-1 (IL-1) including IL-1 alpha and IL-1 beta, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin 5 (IL-5), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-13 (IL-13), Interleukin-15 (IL-15), Interleukin-18 (IL-18), Interleukin-20 (IL-20), Tumor Necrosis Factor-alpha (TNF-a), Tumor Necrosis Factor-beta (TNF-b), Interferon-gamma (INF-g), Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Macrophage Colony stimulating factor (M-CSF), Placenta Growth Factor (PLGF), Nerve Growth Factor (NGF), Keratinocyte Growth Factor (KGF), Bone morphogenesis Protein (BMP-4), Hepatocyte Growth Factor (HGF), Leptin, Noggin, and Thymosin beta 4.
17. The skin caredermatological composition of claim 1 wherein said growth factor or cytokine originates from corresponding human gene sequence.
18. The skin caredermatological composition of claim 1 wherein said growth factor or cytokine originates from synthesized gene corresponding to human gene sequence for respective growth factor or cytokine.
19. The skin caredermatological composition of claim wherein the transgenic plant extract contains dehydrins andor globulins or other seed proteins.
20. The skin caredermatological composition of claim 1 wherein the composition is in the form selected from creams, lotions, gels, dressings, shampoos, tinctures, pastes, ointments, salves, powders, liquid or semiliquid formulations, serums, patches, liposomal preparations, solutions, suspensions, liposome suspensions, WO or OW emulsions, ointments, pomades and pastes and a skin softener cream, a facial pack, a massage cream, and a nutrient cream or a nutrient emulsion.
21. A skin caredermatological composition comprising at least one growth factor derived from a transgenic plant and a protein stabilizing formula comprising glycerol, and purified water q.s.
22. The skin caredermatological composition of claim 21 further comprising a salt selected from sodium chloride, potassium chloride and calcium chloride.
23. The skin caredermatological composition of claim 21, further comprising hyaluronic acid.
24. The skin caredermatological composition of claim 22, comprising a growth factor derived from a transgenic plant and a protein stabilizing formula comprising at least the following ingredients (% by weight): glycerol in the range from 10 to 90%, calcium chloride in the range from 0,1 mM to 200 mM, buffering agent and purified water q.s.
25. The skin caredermatological composition of claim 21 which does not contain a further antimicrobial agent or preservative.
26. The skin caredermatological composition of claim 21 wherein said growth factor is one or more selected from the group consisting of Epidermal Growth Factor (EGF), Vascular Epithelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) including PDGF-AA, PDGF-BB, and PDGF-Rb, Fibroblast Growth Factors (FGFs) including FGF-a, and FGF-b FGF-4 and FGF-6, Transforming Growth Factors-beta (TGFs-b) including TGF beta-1, TGF beta-2, TGF beta-3, Transforming Growth Factor-alpha (TGF-a), Erythropoietin (Epo), Insulin-Like Growth Factor-I (IGF-I), Insulin-Like Growth Factor-II (IGF-II), Interleukin-1 (IL-1) including IL-1 alpha and IL-1 beta, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin 5 (IL-5), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-13 (IL-13), Interleukin-15 (IL-15), Interleukin-18 (IL-18), Interleukin-20 (IL-20), Tumor Necrosis Factor-alpha (TNF-a), Tumor Necrosis Factor-beta (TNF-b), Interferon-gamma (INF-g), Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Macrophage Colony stimulating factor (M-CSF), Placenta Growth Factor (PLGF), Nerve Growth Factor (NGF), Keratinocyte Growth Factor (KGF), Bone morphogenesis Protein (BMP-4), Hepatocyte Growth Factor (HGF), Leptin, Noggin, and Thymosin beta 4.
27-30. (canceled)
31. A method of manufacturing a topical product comprising mixing together a hyaluronic acid, at least one excipient and transgenic plant extract comprising a growth factor selected from Epidermal Growth Factor (EGF), Vascular Epithelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) including PDGF-AA, PDGF-BB, and PDGF-Rb, Fibroblast Growth Factors (FGFs) including FGF-a, and FGF-b FGF-4 and FGF-6, Transforming Growth Factors-beta (TGFs-b) including TGF beta-1, TGF beta-2, TGF beta-3, Transforming Growth Factor-alpha (TGF-a), Erythropoietin (Epo), Insulin-Like Growth Factor-I (IGF-I), Insulin-Like Growth Factor-II (IGF-II), Interleukin-1 (IL-1) including IL-1 alpha and IL-1 beta, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin 5 (IL-5), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-10 (IL-10), Interleukin-13 (IL-13), Interleukin-15 (IL-15), Interleukin-18 (IL-18), Interleukin-20 (IL-20), Tumor Necrosis Factor-alpha (TNF-a), Tumor Necrosis Factor-beta (TNF-b), Interferon-gamma (INF-g), Granulocyte Colony Stimulating Factor (G-CSF), Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Macrophage Colony stimulating factor (M-CSF), Placenta Growth Factor (PLGF), Nerve Growth Factor (NGF), Keratinocyte Growth Factor (KGF), Bone morphogenesis Protein (BMP-4), Hepatocyte Growth Factor (HGF), Leptin, Noggin, and Thymosin beta 4.
32. The method of claim 31 wherein said at least one excipient comprises glycerol, calcium chloride and water.
33. The method of claim 31 wherein said transgenic plant extract is barley seed extract.
34. The method of claim 31 further comprising isolating said growth factor from said transgenic plant extract.
35. (canceled)
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of associating a plurality of objects, the method comprising the steps of:
defining, by use of a real-time locating system (RTLS), a physical space;
determining, by use of a real-time locating system (RTLS), that a patient and a medical device are within the physical space;
upon a determination that a patient and a medical device are within the physical space, associating the patient with the medical device;
determining, by use of the real-time locating system (RTLS), that at least one of a caregiver, a medication, and a medical substance is within the physical space; and
upon a determination that at least one of a caregiver, a medication, and a medical substance is within the physical space, associating such with the medical device.
2. The method of claim 1, further comprising the step of downloading one or more operating parameters to the medical device from a database, wherein the operating parameters are associated with a procedure that has been ordered for the patient.
3. The method of claim 1, wherein the association of the patient with the medical device occurs automatically upon a determination that a patient and a medical device are within the physical space.
4. The method of claim 1, wherein the association of the patient with the medical device is confirmed upon selection of the patient by the caregiver when identifying information of the patient is presented to the caregiver via electronic means.
5. The method of claim 2, wherein the associating of the medication or the medical substance automatically occurs after the medical device has confirmed, by comparison to the one or more operating parameters, that the medication or medical substance has been ordered for the patient.
6. The method of claim 1, further comprising the step of uploading one or more data records from the medical device to a database, wherein the data records are associated with a procedure that has been performed for the patient.
7. The method of claim 6, further comprising the step of uploading one or more data records to an external system that comprises at least one of an AdmitDischargeTransfer (ADT) system, a Medication Administration Record (MAR) system, a billing system, a medical device database, and a portable device carried by a doctor or a nurse.
8. The method of claim 1, further comprising the steps of:
determining that more than one patient is within the physical space;
presenting identifications of the more than one patient to the caregiver; and
accepting a selection from the caregiver of the more than one patient with whom the medical device is to be associated.
9. The method of claim 1, wherein the association of the caregiver to the medical device is transitory.
10. The method of claim 1, further comprising the steps of:
determining whether a caregiver is within the physical space; and
allowing access to the medical device only when the caregiver is within the physical space.
11. The method of claim 9, further comprising the step of controlling access to the medical device according to privileges associated with the medical device assigned to the caregiver.
12. The method of claim 11, wherein the access to the medical device is controlled according to the highest privileges of caregivers within the physical space.
13. The method of claim 1, further comprising the steps of:
determining that more than one caregiver is within the physical space;
presenting the identification of the caregivers on the medical device; and
accepting a selection of the caregiver with whom actions on the medical device are to be associated.
14. The method of claim 1, further comprising the steps of:
identifying actions or events related to the medical device;
identifying one or more caregivers that are within the physical space when the action or event occurred; and
recording the action or event and the identities of the caregivers.
15. The method of claim 1, further comprising the steps of:
identifying a medication that is within the physical space; and
configuring the medical device to be used with the medication.
16. The method of claim 15, further comprising the step of recording the identification of the patient, the identification of the caregiver, and the identification of the medication when the medical device is activated.
17. The method of claim 1, further comprising the steps of:
identifying a medication that is within the physical space;
verifying that the patient has a prescription comprising the medication; and
configuring the medical device according to the prescription.
18. The method of claim 17, further comprising the steps of:
presenting the identifications of medications to the caregiver when more than one medication is in the physical space; and
accepting a selection from the caregiver of the identification of the medication that is to be delivered by the medical device.
19. A system comprising:
a real-time locating system (RTLS) configured to identify an RTLS tag that is within a physical space defined by the real-time locating system (RTLS), wherein the RTLS tag is associated with one of a patient, a caregiver, a medical device, a medication, and a medical; and
a processor coupled to a real-time locating system (RTLS), wherein the processor is configured (i) to receive the identification of the tagged patient and upon receipt of the identification of the tagged patient to automatically associate the tagged patient with the physical space, and (ii) to receive the identification of the tagged medical device and upon receipt of the identification of the tagged medical device to automatically associate the tagged medical device with the tagged patient in the physical space.
20. The system of claim 19, wherein the processor is further configured to receive the identification of the caregiver in the physical space and automatically associate the tagged caregiver with the tagged medical device in the physical space.
21. The system of claim 19, where the processor is configured (i) to receive identification of a plurality of caregivers and to output, on a graphic display, a list of the plurality of caregivers to be selected for operation of the medical device; and (ii) to associate actions relating to the tagged medical device with the caregiver selected.
22. The system of claim 19, wherein the processor is configured to automatically record the assignment of the tagged medical device to the tagged patient in a database.
23. The system of claim 19, wherein the processor is configured to communicate with a prescription database that comprises at least one prescription for the tagged patient, wherein the prescription comprises one or more operating parameters associated with the tagged medical device, and wherein the processor is configured to retrieve the operating parameters from the prescription and download the operating parameters to the tagged medical device.
24. The system of claim 19, wherein the processor is further configured to associate a tagged medication identified by a real-time locating system (RTLS) to be within the physical space with the tagged medical device, identify a prescription in the prescription database that comprises the medication, and retrieve the operating parameters from the identified prescription.
25. The system of claim 19, wherein the processor is configured to upload one or more data records associated with a procedure that has been performed for the tagged patient using the medical device and to store the data records in the database.
26. The system of claim 25, wherein the processor is configured to upload one or more data records to an external system that comprises at least one of an AdmitDischargeTransfer (ADT) system, a Medication Administration Record (MAR) system, a billing system, a medical device database, and a portable device carried by a doctor or a nurse.
27. The system of claim 19, wherein the processor is further configured to present identifications of one or more patients identified by a real-time locating system (RTLS) to be within the physical space to a caregiver identified by a real-time locating system (RTLS) to be within the physical space and to accept a selection from the caregiver of the patient with whom the tagged medical device is to be associated.
28. The system of claim 19, wherein the processor is further configured to control the tagged medical device to allow access according to whether a caregiver identified by a real-time locating system (RTLS) is within the physical space.
29. The system of claim 28, wherein the processor is further configured to control the tagged medical device to allow access according to the highest privileges of caregivers within the physical space, wherein each caregiver has been assigned one or more privileges associated with the tagged medical device.
30. The system of claim 19, wherein the processor is further configured to store in the database a data record of actions and events associated with the medical device with the identification of all caregivers identified by a real-time locating system (RTLS) to be within the physical space at the time of the action or event.